X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49) 49
animals (38) 38
kala-azar (31) 31
male (29) 29
female (27) 27
index medicus (26) 26
leishmaniasis, visceral - epidemiology (25) 25
visceral leishmaniasis (25) 25
adult (24) 24
infectious diseases (23) 23
child, preschool (22) 22
leishmaniasis (22) 22
child (20) 20
parasitology (20) 20
mediterranean leishmaniasis (18) 18
tropical medicine (18) 18
adolescent (17) 17
epidemiology (16) 16
infant (16) 16
middle aged (16) 16
leishmaniasis, visceral - diagnosis (14) 14
microbiology (14) 14
cutaneous leishmaniasis (13) 13
immunology (13) 13
mediterranean region (13) 13
parasitic diseases (13) 13
leishmania infantum (12) 12
aged (11) 11
infection (11) 11
canine leishmaniasis (10) 10
prevalence (10) 10
disease (9) 9
leishmaniasis, visceral - drug therapy (9) 9
leishmaniasis, visceral - immunology (9) 9
liposomal amphotericin-b (9) 9
mediterranean visceral leishmaniasis (9) 9
public, environmental & occupational health (9) 9
dogs (8) 8
health aspects (8) 8
infections (8) 8
amphotericin b - therapeutic use (7) 7
antiprotozoal agents - therapeutic use (7) 7
diagnosis (7) 7
infant, newborn (7) 7
mediterranean region - epidemiology (7) 7
travel (7) 7
aged, 80 and over (6) 6
diagnosis, differential (6) 6
drug therapy (6) 6
leishmaniasis, visceral - blood (6) 6
leishmaniasis, visceral - parasitology (6) 6
mediterranean islands (6) 6
parasites (6) 6
polymerase chain reaction (6) 6
research (6) 6
retrospective studies (6) 6
risk factors (6) 6
skin-test (6) 6
ambisome (5) 5
antigens (5) 5
azar dermal leishmaniasis (5) 5
diseases (5) 5
enzyme-linked immunosorbent assay (5) 5
human-population (5) 5
incidence (5) 5
infectious disease (5) 5
leishmania infantum - immunology (5) 5
leishmania infantum - isolation & purification (5) 5
leishmaniasis, visceral - transmission (5) 5
life sciences (5) 5
therapy (5) 5
age factors (4) 4
antibodies, protozoan - blood (4) 4
arctic medicine. tropical medicine (4) 4
baringo district (4) 4
brazil (4) 4
dna (4) 4
fever (4) 4
human-immunodeficiency-virus (4) 4
immunocompromised host (4) 4
infantum (4) 4
insect vectors - parasitology (4) 4
leishmania (4) 4
leishmania - immunology (4) 4
leishmania - isolation & purification (4) 4
leishmania donovani (4) 4
leishmaniasis - diagnosis (4) 4
leishmaniasis - epidemiology (4) 4
medicine & public health (4) 4
microbiology and parasitology (4) 4
mucocutaneous leishmaniasis (4) 4
polymerase-chain-reaction (4) 4
psychodidae - parasitology (4) 4
public aspects of medicine (4) 4
public health (4) 4
research article (4) 4
sensitivity and specificity (4) 4
skin tests (4) 4
sodium stibogluconate (4) 4
vector-borne diseases (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS neglected tropical diseases, ISSN 1935-2727, 08/2014, Volume 8, Issue 8, p. e3021
Journal Article
PLoS Neglected Tropical Diseases, ISSN 1935-2727, 03/2017, Volume 11, Issue 3, p. e0005484
Background The Leishmania developmental life cycle within its sand fly vector occurs exclusively in the lumen of the insect's digestive tract in the presence... 
TRANSMISSION | MICROBIAL COMMUNITIES | LUTZOMYIA-LONGIPALPIS | CENTRAL TUNISIA | SAND FLIES | INFECTION | SERRATIA-MARCESCENS | DIPTERA PSYCHODIDAE | GRADIENT GEL-ELECTROPHORESIS | GUT BACTERIA | PARASITOLOGY | TROPICAL MEDICINE | Metagenomics | Bacteria - isolation & purification | Animals | Insect Vectors | Phlebotomus - microbiology | Gastrointestinal Microbiome | Bacteria - classification | Bacteriological Techniques | Mediterranean Region | Seasons | Bacteria - genetics | Sequence Analysis, DNA | Physiological aspects | Kala-azar | Microbiota (Symbiotic organisms) | Health aspects | Diptera | Distribution | Chronic infection | Combustion | Biochemistry | Phylogeny | pH effects | Biodiversity | Tropical diseases | Microorganisms | Parasitic diseases | Etiology | Visceral leishmaniasis | Biomolecules | Intestinal microflora | Bioinformatics | Public health | Deoxyribonucleic acid--DNA | Carbohydrates | Pathogens | Malaria | Vectors | Leishmaniasis | Vectors (Biology) | Zoonoses | Infectious diseases | Disease transmission | Death | Chagas' disease | Health care | Populations | Laboratories | Genes | Ribosomal DNA | Viruses | Infections | Parasites | Species diversity | Intestine | Bacteria | Digestive tract | Vector-borne diseases | Nucleotide sequence | Colonies | Abundance | Ecology | Preventive medicine | Population decline | Medicine | Aridity | Lysis | Life cycles | Invertebrate Zoology | Bacteria/classification | Bacteria/genetics | Animal biology | Bacteria/isolation & purification | Life Sciences | Human health and pathology | Phlebotomus/microbiology | Deoxyribonucleic acid | Health | DNA
Journal Article
Journal of Parasitic Diseases, ISSN 0971-7196, 6/2018, Volume 42, Issue 2, pp. 162 - 170
Visceral leishmaniasis (VL) is a tropical infectious disease, which is called Mediterranean visceral leishmaniasis (MVL) in the Mediterranean area. In spite of... 
Vaccine target | Medicine & Public Health | Mediterranean visceral leishmaniasis | Proteomics | Health Promotion and Disease Prevention | Infectious Diseases | Medicine/Public Health, general | Antigens | Medical research | Kala-azar | Usage | Communicable diseases | Medicine, Experimental | Vaccines | Review
Journal Article
Experimental Parasitology, ISSN 0014-4894, 2009, Volume 123, Issue 3, pp. 218 - 225
Journal Article
Tropical Medicine & International Health, ISSN 1360-2276, 10/2008, Volume 13, Issue 10, pp. 1272 - 1276
Summary Until the early 1990s, pentavalent antimony was the only documented first‐line drug employed for the treatment of zoonotic visceral leishmaniasis (VL)... 
Leishmania infantum | therapy | terapia | miltéfosine | amphotericin B | miltefosine | antimoine pentavalent | leishmaniasis visceral Mediterránea | Anfotericina B | antimonio pentavalente | Mediterranean visceral leishmaniasis | thérapie | leishmaniose viscérale méditerranéenne | pentavalent antimony | amphotéricine B | Miltefosine | Therapy | Amphotericin B | Pentavalent antimony | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | AMPHOTERICIN-B | TROPICAL MEDICINE | Meglumine - therapeutic use | Humans | Middle Aged | Clinical Protocols | Antiprotozoal Agents - economics | Child, Preschool | Male | Leishmaniasis, Visceral - immunology | Antimony Sodium Gluconate - economics | Immunocompromised Host - drug effects | Middle East | Aged, 80 and over | Adult | Female | Child | Africa, Northern | Europe | Meglumine - economics | Leishmaniasis, Visceral - drug therapy | Animals | Adolescent | Aged | Israel | Amphotericin B - therapeutic use | Antimony Sodium Gluconate - therapeutic use | Antiprotozoal Agents - therapeutic use | Leishmaniasis, Visceral - economics | Amphotericin B - economics | Kala-azar | Drug therapy | Parasitic diseases | Index Medicus | Life Sciences | Medication | Antimony Sodium Gluconate | Pharmaceutical sciences | Parasitology | Microbiology and Parasitology | Antiprotozoal Agents | Leishmaniasis, Visceral | Meglumine | Immunocompromised Host
Journal Article